Moreover, phenotypic differences in TLS characterized by different expression levels of immune checkpoints have divergent effects on the prognosis of cancer patients.[82] Similarly, we also detected the upregulation of TIM‐3 in the T cells of TLSs in liver metastases, which could be another potential mechanism underlying the poor response to immunotherapy. This evidence concerns the gene HAVCR2 and cancer.